EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression

Na Wang, Chun Zhang iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25063086 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Na Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 103-mal zitiert (Crossref) und nennt 237 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Key Research and Development Program of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic kidney disease (DKD) is a major cause of chronic kidney disease (CKD), and it heightens the risk of cardiovascular incidents. The pathogenesis of DKD is thought to involve hemodynamic, inflammatory, and metabolic factors that converge on the fibrotic pathway. Genetic predisposition and unhealthy lifestyle practices both play a significant role in the development and progression of DKD. In spite of the recent emergence of angiotensin receptors blockers (ARBs)/angiotensin converting enzyme inhibitor (ACEI), sodium-glucose cotransporter 2 (SGLT2) inhibitors, and nonsteroidal mineralocorticoid receptors antagonists (NS-MRAs), current therapies still fail to effectively arrest the progression of DKD. Glucagon-like peptide 1 receptor agonists (GLP-1RAs), a promising class of agents, possess the potential to act as renal protectors, effectively slowing the progression of DKD. Other agents, including pentoxifylline (PTF), selonsertib, and baricitinib hold great promise as potential therapies for DKD due to their anti-inflammatory and antifibrotic properties. Multidisciplinary treatment, encompassing lifestyle modifications and drug therapy, can effectively decelerate the progression of DKD. Based on the treatment of heart failure, it is recommended to use multiple drugs in combination rather than a single-use drug for the treatment of DKD. Unearthing the mechanisms underlying DKD is urgent to optimize the management of DKD. Inflammatory and fibrotic factors (including IL-1, MCP-1, MMP-9, CTGF, TNF-a and TGF-β1), along with lncRNAs, not only serve as diagnostic biomarkers, but also hold promise as therapeutic targets. In this review, we delve into the potential mechanisms and the current therapies of DKD. We also explore the additional value of combing these therapies to develop novel treatment strategies. Drawing from the current understanding of DKD pathogenesis, we propose HIF inhibitors, AGE inhibitors, and epigenetic modifications as promising therapeutic targets for the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesRenal Insufficiency, ChronicDiabetes Mellitus, Type 2HumansAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsKidney

Stichwörter der Autor:innen

biomarkerschronic kidney diseasediabetic kidney diseasemolecular mechanismstherapies

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

ORCID-Profile: Chun Zhang

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Key Research and Development Program of Hubei Province

Zitieren

APA

Wang, N., & Zhang, C. (2024). Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25063086

Vancouver

Wang N, Zhang C. Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25063086

BibTeX
@article{Wang2024,
  author = {Wang, Na and Zhang, Chun},
  title = {Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25063086}
}
Kostenlos starten →